专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011053779A2 METHODS FOR TREATING CANCER IN PATIENTS HAVING IGF-1R INHIBITOR RESISTANCE 审中-公开
标题翻译：治疗患有IGF-1R抑制剂抗性的患者的癌症的方法
公开(公告)号：WO2011053779A2
公开(公告)日：2011-05-05
申请号：PCT/US2010/054704
申请日：2010-10-29
申请人： BRISTOL-MYERS SQUIBB COMPANY , HUANG, Fei , CARBONI, Joan M.
发明人： HUANG, Fei , CARBONI, Joan M.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： A method for treating cancer comprising identifying a mammal that overexpresses breast cancer resistance protein; and administering to said mammal a pharmaceutical composition comprising a therapeutically effective amount of ixabepilone. In one aspect, the mammal is not administered an agent that is susceptible to breast cancer resistance protein overexpression resistance. In another aspect, the cancer is a solid tumor.
摘要翻译：治疗癌症的方法，包括鉴定过表达乳腺癌抗性蛋白质的哺乳动物; 并向所述哺乳动物施用包含治疗有效量的伊沙贝比隆的药物组合物。在一个方面，哺乳动物未被施用易受乳腺癌抗性蛋白质过表达抗性的药剂。另一方面，癌症是一种实体瘤。

2. 发明申请

WO2008144345A2 BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO INSULIN GROWTH FACTOR-1 RECEPTOR MODULATORS 审中-公开
标题翻译：生物标记物和确定胰岛素生长因子-1受体调节剂敏感性的方法
公开(公告)号：WO2008144345A2
公开(公告)日：2008-11-27
申请号：PCT/US2008/063621
申请日：2008-05-15
申请人： BRISTOL-MYERS SQUIBB COMPANY , HUANG, Fei , HAN, Xia , HAFEZI, Rameh , CHEN, Jiwen , ROBINSON, Douglas, Michael , WITTENBERG, Gayle, M. , DONGRE, Ashok, Ramesh , CARBONI, Joan, M. , ATTAR, Ricardo, M. , HURLBURT, Warren , GOTTARDIS, Marco, M.
发明人： HUANG, Fei , HAN, Xia , HAFEZI, Rameh , CHEN, Jiwen , ROBINSON, Douglas, Michael , WITTENBERG, Gayle, M. , DONGRE, Ashok, Ramesh , CARBONI, Joan, M. , ATTAR, Ricardo, M. , HURLBURT, Warren , GOTTARDIS, Marco, M.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158
摘要： IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer.
摘要翻译： IGF1R生物标志物可用于鉴定和监测将对治疗癌症治疗的治疗反应的哺乳动物的方法，其包括施用IGF1R调节剂，其中所述方法包括（a）将哺乳动物暴露于IGF1R调节剂和（b）在哺乳动物中测量所述至少一种生物标志物的水平，其中在（b）中测量的至少一种生物标志物的水平的差异与尚未暴露于IGF1R调节剂的哺乳动物中的生物标志物的水平相比表明哺乳动物将对治疗癌症的方法进行反应和（c）其中暴露于IGF1R调节剂后哺乳动物中的生物标志物的水平指示哺乳动物对治疗癌症的方法有治疗反应。

3. 发明申请

WO2006005035A2 IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING ACTIVITY OF COMPOUNDS THAT INTERACT WITH AND/OR MODULATE PROTEIN TYROSINE KINASES AND/OR PROTEIN TYROSINE PATHWAYS IN LUNG CANCER CELLS 审中-公开
标题翻译：识别用于预测与肺癌细胞相互作用和/或调节蛋白酪氨酸激酶和/或蛋白质酪氨酸途径的化合物的活性的多核苷酸的鉴定
公开(公告)号：WO2006005035A2
公开(公告)日：2006-01-12
申请号：PCT/US2005/023687
申请日：2005-06-29
申请人： BRISTOL-MYERS SQUIBB COMPANY , HUANG, Fei , REEVES, Karen A. , HAN, Xia , FAIRCHILD, Craig R. , SHAW, Peter
发明人： HUANG, Fei , REEVES, Karen A. , HAN, Xia , FAIRCHILD, Craig R. , SHAW, Peter
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158
摘要： The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., lung cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Ephr. These polynucleotides have been shown, through a weighted voting cross validation program, to have utility in predicting the resistance and sensitivity of lung cell lines to the compounds. The expression level of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compounds, comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., lung cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process.
摘要翻译：本发明描述了已经发现与将细胞（例如肺细胞系）的相对固有敏感性或抗性相关联的化合物与与蛋白酪氨酸激酶相互作用并调节，例如抑制蛋白质酪氨酸激酶（例如，，Src家族酪氨酸激酶的成员，例如Src，Fgr，Fyn，Yes，Blk，Hck，Lck和Lyn，以及其他蛋白酪氨酸激酶，包括Bcr-abl，Jak，PDGFR，c-kit和 EPHR。已经通过加权投票交叉验证程序显示了这些多核苷酸可用于预测肺细胞系对化合物的抵抗力和敏感性。一些多核苷酸的表达水平通过用特定蛋白酪氨酸激酶抑制剂化合物的治疗来调节，因此表明这些多核苷酸参与蛋白酪氨酸激酶信号转导途径，例如Src酪氨酸激酶。这些多核苷酸的表达水平与药物敏感性或抗性高度相关并且通过用化合物处理而被调节的多核苷酸包括用于预测药物反应的方法中的多核苷酸预测物或标志物组，以及疾病管理中的预后或诊断指标，特别是在那些疾病领域，例如肺癌，其中通过蛋白酪氨酸激酶途径的信号，例如Src酪氨酸激酶途径参与疾病过程。

4. 发明申请

WO2004097030A2 PROGNOSTIC BREAST CANCER BIOMARKERS 审中-公开
公开(公告)号：WO2004097030A2
公开(公告)日：2004-11-11
申请号：PCT/US2004/013076
申请日：2004-04-28
申请人： BRISTOL-MYERS SQUIBB COMPANY , KAROLINSKA INNOVATIONS AB , BERGH, Jonas , PAWITAN, Yudi , HALL, Per , AMLER, Lukas, C. , HAN, Xia , HUANG, Fei , SHAW, Peter
发明人： BERGH, Jonas , PAWITAN, Yudi , HALL, Per , AMLER, Lukas, C. , HAN, Xia , HUANG, Fei , SHAW, Peter
IPC分类号： C12Q
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118
摘要： A method of identifying a mammal at increased risk for developing breast cancer comprising the steps of obtaining a biological sample from the mammal, measuring in said biological sample the level of at least one biomarker, correlating said level of at least one biomarker with a baseline level, identifying a mammal at increased risk for developing breast cancer based on said correlation.
摘要翻译：一种识别发展中的乳腺癌风险增加的哺乳动物的方法，包括以下步骤：从所述哺乳动物获得生物样品，在所述生物样品中测量至少一种生物标志物的水平，将所述至少一种生物标志物的水平与基线水平相关联基于所述相关性鉴定发生乳腺癌风险增加的哺乳动物。

5. 发明申请

WO2008086342A3 IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING ACTIVITY OF COMPOUNDS THAT INTERACT WITH AND/OR MODULATE PROTEIN TYROSINE KINASES AND/OR PROTEIN TYROSINE KINASE PATHWAYS IN PROSTATE CELLS 审中-公开
公开(公告)号：WO2008086342A3
公开(公告)日：2008-07-17
申请号：PCT/US2008/050495
申请日：2008-01-08
申请人： BRISTOL-MYERS SQUIBB COMPANY , HUANG, Fei , CLARK, Edwin, A. , WANG, Xi-de
发明人： HUANG, Fei , CLARK, Edwin, A. , WANG, Xi-de
IPC分类号： C12Q1/68
摘要： The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., prostate cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Eph receptors. These polynucleotides have been shown to have utility in predicting the resistance and sensitivity of prostate cell lines to the compounds. The expression level or phosphorylation status of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compounds, comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., prostate cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process.

6. 发明申请

WO2006096473A3 IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING ACTIVITY OF COMPUNDS THAT INTERACT WITH AND/OR MODULATE PROTEIN TYROSINE KINASES AND/OR PROTEIN TYROSINE KINASE PATHWAYS IN BREAST CELLS 审中-公开
公开(公告)号：WO2006096473A3
公开(公告)日：2006-09-14
申请号：PCT/US2006/007487
申请日：2006-03-02
申请人： BRISTOL-MYERS SQUIBB COMPANY , HUANG, Fei , HAN, Xia , REEVES, Karen A. , AMLER, Lukas C. , FAIRCHILD, Craig R. , LEE, Francis Y. , SHAW, Peter
发明人： HUANG, Fei , HAN, Xia , REEVES, Karen A. , AMLER, Lukas C. , FAIRCHILD, Craig R. , LEE, Francis Y. , SHAW, Peter
IPC分类号： C12Q1/68
摘要： The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., breast cell lines, to treatment with the compound BMS-A that interacts with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, BIk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Eph receptors. These polynucleotides have been shown, through a weighted voting cross validation program, to have utility in predicting the resistance and sensitivity of breast cell lines to the compound BMS-A. The expression level or phosphorylation status of some polynucleotides is regulated by treatment with the protein tyrosine kinase inhibitor compound BMS-A, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase.

7. 发明申请

WO2004020583A2 IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING ACTIVITY OF COMPOUNDS THAT INTERACT WITH AND/OR MODULATE PROTEIN TYROSINE KINASES AND/OR PROTEIN TYROSINE KINASE PATHWAYS IN BREAST CELLS 审中-公开
标题翻译：用于预测与乳腺细胞相互作用和/或调节蛋白酪氨酸激酶和/或蛋白酪氨酸激酶途径的化合物活性的多核苷酸的鉴定
公开(公告)号：WO2004020583A2
公开(公告)日：2004-03-11
申请号：PCT/US2003/026491
申请日：2003-08-26
申请人： BRISTOL-MYERS SQUIBB COMPANY , HUANG, Fei , HAN, Xia , REEVES, Karen, A. , AMLER, Lucas , FAIRCHILD, Craig, R. , LEE, Francis, Y. , SHAW, Peter
发明人： HUANG, Fei , HAN, Xia , REEVES, Karen, A. , AMLER, Lucas , FAIRCHILD, Craig, R. , LEE, Francis, Y. , SHAW, Peter
IPC分类号： C12N
CPC分类号： C07K14/47 , A61K38/00 , C12Q1/6837 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158
摘要： The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., breast cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Eph receptors. These polynucleotides have been shown, through a weighted voting cross validation program, to have utility in predicting the resistance and sensitivity of breast cell lines to the compounds. The expression level or phosphorylation status of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compounds, comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., breast cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process.
摘要翻译：本发明描述了已被发现与多种细胞相关的细胞（例如，乳腺细胞系）与用蛋白酪氨酸激酶相互作用并调节，例如抑制蛋白酪氨酸激酶（例如，，Src家族酪氨酸激酶的成员，例如Src，Fgr，Fyn，Yes，Blk，Hck，Lck和Lyn，以及其它蛋白酪氨酸激酶，包括Bcr-abl，Jak，PDGFR，c-kit和 Eph受体。已经通过加权投票交叉验证程序显示了这些多核苷酸可用于预测乳腺细胞系对化合物的抵抗力和敏感性。一些多核苷酸的表达水平或磷酸化状态通过用特定蛋白质酪氨酸激酶抑制剂化合物的处理来调节，从而表明这些多核苷酸参与蛋白酪氨酸激酶信号转导途径，例如Src酪氨酸激酶。这些多核苷酸的表达水平与药物敏感性或抗性高度相关并且通过用化合物处理而被调节的多核苷酸包括用于预测药物反应的方法中的多核苷酸预测物或标志物组，以及疾病管理中的预后或诊断指标，特别是在那些疾病领域，例如乳腺癌，其中通过蛋白酪氨酸激酶途径的信号传导，例如Src酪氨酸激酶途径参与疾病过程。

8. 发明申请

WO2003062395A3 PREDICTOR SETS FOR TYROSINE KINASE PATHWAYS 审中-公开
公开(公告)号：WO2003062395A3
公开(公告)日：2003-07-31
申请号：PCT/US2003/001981
申请日：2003-01-17
申请人： BRISTOL-MYERS SQUIBB COMPANY , HUANG, Fei , FAIRCHILD, Craig, R. , LEE, Francis, Y. , SHAW, Peter
发明人： HUANG, Fei , FAIRCHILD, Craig, R. , LEE, Francis, Y. , SHAW, Peter
IPC分类号： C07K14/00
摘要： The present invention describes polynucleotides and polypeptides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., colon cell lines, to treatment with compounds that interact with and inhibit src tyrosine kinases. These polynucleotides and polypeptides have been shown, through a weighted voting cross validation program, to have utility in predicting the intrinsic resistance and sensitivity of colon cell lines to these compounds. Such polynucleotides and polypeptides whose expression levels correlate highly with drug sensitivity or resistance comprise predictor or marker sets of polynucleotides and polypeptides that are useful in methods of predicting drug response and as prognostic or diagnostic indicators in disease management, particularly in those disease areas in which signaling through src tyrosine kinase of the src tyrosine kinase pathway is involved with the disease process.

9. 发明申请

WO2013056069A1 METHODS FOR SELECTING AND TREATING CANCER IN PATIENTS WITH IGF-1R/IR INHIBITORS 审中-公开
标题翻译：用IGF-1R / IR抑制剂选择和治疗癌症患者的方法
公开(公告)号：WO2013056069A1
公开(公告)日：2013-04-18
申请号：PCT/US2012/059982
申请日：2012-10-12
申请人： BRISTOL-MYERS SQUIBB COMPANY
发明人： HUANG, Fei , CHANG, Han , CARBONI, Joan M.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6881 , A61K31/53 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158
摘要： The present invention relates generally to the field of pharmacogenomics, and more specifically to methods and procedures to determine drug sensitivity in patients to allow the identification of individualized genetic profiles which will aid in selecting cancer patients that are responsive to IGF-1R/IR inhibition.
摘要翻译：本发明一般涉及药物基因组学领域，更具体地涉及确定患者药物敏感性的方法和程序，以允许鉴定将有助于选择对IGF-1R / IR抑制作用有反应的癌症患者的个体化遗传图谱。

10. 发明公开

EP2766497A1 METHODS FOR SELECTING AND TREATING CANCER IN PATIENTS WITH IGF-1R/IR INHIBITORS 审中-公开
标题翻译：选择和治疗癌症的患者法IGF-1R / IR抑制剂
公开(公告)号：EP2766497A1
公开(公告)日：2014-08-20
申请号：EP12780361.7
申请日：2012-10-12
申请人： Bristol-Myers Squibb Company
发明人： HUANG, Fei , CHANG, Han , CARBONI, Joan M.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6881 , A61K31/53 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158
摘要： The present invention relates generally to the field of pharmacogenomics, and more specifically to methods and procedures to determine drug sensitivity in patients to allow the identification of individualized genetic profiles which will aid in selecting cancer patients that are responsive to IGF-1R/IR inhibition.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式